文献速递乳腺癌

肿瘤浸润淋巴细胞作为乳腺癌生物标志物的历程:免疫检查点抑制时代的临床效用

The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
PubMed 文献 · Ann Oncol · 2021-07-24

2014年描述了一种在H&E染色切片上量化乳腺癌肿瘤浸润淋巴细胞(TIL)百分比的方法,经全球工作组标准化并免费培训。全球超2万例原发乳腺癌样本数据显示TIL与三阴性乳腺癌(TNBC)和HER2+乳腺癌更好预后稳健相关,已纳入多个国际指南和国家病理报告标准。TIL是早期TNBC首个生物学预后标志物,其预后效应呈线性,30%-50%值被建议用于化疗降阶梯研究。免疫检查点药物获批后,研究聚焦TIL在免疫检查点治疗中的临床效用,新兴数据提示TIL数量可帮助识别从PD-1/PD-L1抑制中获益最多的患者,晚期TNBC和HER2+疾病中TIL cut-off 5%或10%联合PD-L1表达可定义「免疫富集」肿瘤。

要点

  • TIL是早期TNBC首个生物学预后标志物,预后效应线性,30%-50%值建议用于化疗降阶梯研究。
  • TIL已纳入多个国际乳腺癌指南和国家常规病理报告标准。
  • 晚期TNBC和HER2+疾病中TIL cut-off 5%或10%联合PD-L1可定义「免疫富集」肿瘤。

核心结论

  • TIL是早期TNBC首个生物学预后标志物,与TNBC和HER2+乳腺癌更好预后稳健相关。
  • TIL数量可帮助识别从PD-1/PD-L1抑制中获益最多的乳腺癌患者。

研究设计与样本

  • 2014年描述了一种在H&E染色切片上量化TIL百分比的方法,无需额外染色。
  • 全球乳腺癌病理学家工作组标准化并测试可重复性,建立免费培训网站。
  • 全球超2万例原发乳腺癌样本收集TIL数据。

主要发现

  • TIL与TNBC和HER2+乳腺癌更好预后稳健相关。
  • TIL预后效应呈线性,30%-50%值被建议用于潜在化疗降阶梯研究。
  • 晚期TNBC和HER2+疾病中TIL cut-off 5%或10%联合PD-L1表达可定义「免疫富集」肿瘤。

关键数值与推荐

  • TIL已纳入多个国际乳腺癌指南和国家常规病理报告标准。
  • 早期TNBC中TIL预后效应线性,30%-50%值建议用于化疗降阶梯研究。
  • 晚期TNBC和HER2+疾病中TIL cut-off 5%或10%联合PD-L1表达定义「免疫富集」肿瘤。

临床怎么用

  • 病理科可常规在H&E切片上量化TIL,无需额外染色。
  • 早期TNBC可依据TIL值(30%-50%)考虑化疗降阶梯研究。
  • 晚期TNBC和HER2+疾病可联合TIL cut-off(5%或10%)与PD-L1表达识别免疫富集患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2014, we described a method to quantify percentage of tumor-infiltrating lymphocytes (TILs) on hematoxylin and eosin-stained slides of breast cancer samples using light microscopy that could be performed easily by pathologists with no extra stains. The aim of detailing the method was to facilitate independent research groups replicating our prognostic findings using TIL quantity in early-stage breast cancers. A global working group of breast pathologists was convened to standardize, test reproducibility, and refine the method. A website was also established which allowed free training (www.tilsinbreastcancer.org). As a result of this work, TIL data have been collected in over 20 000 primary breast cancer samples worldwide and the robust associations with better prognoses in triple-negative breast cancer (TNBC) and HER2+ BC have been confirmed. This has resulted in the inclusion of the TIL biomarker in several international breast cancer guidelines as well as in national criteria for routine pathology reporting. TIL therefore represents the first biological prognostic biomarker for early-stage TNBCs, and here its prognostic effect is linear, with values of 30%-50% being suggested as suitable for use in potential chemotherapy de-escalation studies. The efficacy of immune checkpoint-targeted agents in breast cancer now provides direct evidence that host immune responses can modify tumor growth in some patients. With the recent granting of accelerated approvals for the first PD-1/PD-L1 targeting agents in early and advanced TNBC, our focus has now moved to investigating the clinical utility of TIL in the setting of immune checkpoint agents, with or without PD-L1 protein assessment. Emerging data suggest that TIL quantity can help clinicians identify patients with breast cancer who benefit most from PD-1/PD-L1 inhibition. In patients with advanced TNBC and HER2+ disease a TIL cut-off of 5% or 10%, with PD-L1 expression can define 'immune-enriched' tumors and currently seems to have the most clinical relevance in this context.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021. PMID: 34311075. doi:10.1016/j.annonc.2021.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。